PowerPoint Presentation

1 of
Published on Video
Go to video
Download PDF version
Download PDF version
Embed video
Share video
Ask about this video

Page 1 (0s)

Pfizer Logo change in all slides. P zer LEADING WITH A PURPOSE 1026 AM (x 4/4/2022.

Page 2 (8s)

Logo change. Pfizer vertical vidK) Deliver first-in-class science 1027 AM 4/4/2022.

Page 3 (16s)

Logo change. Pfizer vertica final p zer Deliver first-in-class science Source the best science in the world. Double our innovation success rate U)13 4/4/2022.

Page 4 (26s)

Remove. Pfizer vertical final Video of Mia in Irdia Addressing current disease challenges and bringing tomorrow's cures to India. Ct19 TAM 4/4/2022.

Page 5 (36s)

Logo change. Pfizer final p zer IPlGzel'fi How Pfizer is making a difference in the management of infections Active stewardship: ensure patients receive the correct antibiotic an r ura on TUAM 4/4/2022.

Page 6 (47s)

Logo change. Pfizer vertical Final video P zel' How Pfizer is making a difference in the management of infections Innovative surveillance tools: to help physicians better curren res ncepa ms l&28AM (x 4/4/2022.

Page 7 (58s)

Logo change. Pfzer vMical final How Pfizer is making a difference in the management of infections Diverse portfolio: medicines to treat and prevent Serious n c nS e wo co•43 11129 AM 4/4/2022.

Page 8 (1m 9s)

Magnex 1 st , 2 nd Meronem and 3 rd Zosyn – check if all logos are correct. All logos sent.

Page 9 (1m 20s)

Update Pfizer Logo. Pfizer vertical Final video p zer Comprehensive Product Portfolio Any-Bacterial Agents DalacinC IBOAM (x 4/4/2022.

Page 10 (1m 29s)

1 st Cresemba , 2 nd Eraxis , 3 rd Vfend – Check all logos are correct. Sent all logos already.

Page 11 (1m 41s)

Check if all logos are correct. Sent all logos already.

Page 12 (1m 52s)

Update Pfizer logo. Pfizer vertical Final video p zer Anti•lnfectives COMMITMENT TOWARDS NEWER INNOVATIVE ANTIBIOTICS (x 4/4/2022.

Page 13 (2m 1s)

Replace this content with Zavicefta content I have sent – Added in the next 2 slides.

Page 14 (2m 14s)

Zaviceft a.

Page 15 (2m 21s)

Ceftazidime- avibactam. Ceftazidime- Third generation cephalosporin Avibactam- non beta lactam- beta lactamase inhibitor First-in-class Inhibition of β-lactamases is covalent but reversible (characteristic that other known β-lactamase inhibitors lack) The activity of AVI is reinstated once acted.

Page 16 (2m 46s)

Ceftazidime – avibactam indications & spectrum of activity.

Page 17 (3m 33s)

Replace this content with Zavicefta content I have sent – Added in the next 2 slides.

Page 18 (3m 46s)

After Zavicefta , Add cresemba slides. Pfizer vertical Final video Anti•lnfectives Decisive action against gram negative pathogens including E. coli, K.pneumoniae&P eruginosag 01:15 (x 4/4/2022.

Page 19 (3m 53s)

Cresemba.

Page 20 (4m 0s)

CRESEMBA® IS THE ONLY AZOLE LICENSED FOR TREATMENT OF BOTH INVASIVE ASPERGILLOSIS AND MUCORMYCOSIS.

Page 21 (4m 30s)

Isavuconazole formulations, strengths and dosage.

Page 22 (4m 55s)

After Cresemba , replace existing Zinforo slides with new slides.

Page 23 (5m 8s)

Zinforo.

Page 24 (5m 15s)

Salient Features. Indicated for the treatment of adult (≥18 years of age) patients with Community-acquired pneumonia and Complicated skin and soft tissue infections ( cSSTI ) 1 First MRSA-active β -lactam with extended spectrum against Gram-positive and Gram-negative bacteria commonly associated with cSSTI 2 Early rapid clinical response by day 3 in cSSTI as recorded in various Trials (CANVAS and COVERS) 3 Day 4 early response in CAP as seen in trials FOCUS 1 and 2. 4,5 Recently recommended in cSSTI as per the Surgical Infectious Society Guideline as the first choice of drug for the management of MRSA SSTI 6.

Page 25 (6m 10s)

Dosage in Adults and Renal Impairment. Simple dosing with no routine monitoring, low risk of drug–drug interaction, no dose adjustment based on bodyweight.

Page 26 (6m 56s)

After Zinforo, will be Atlas. Replace Pfizer logo.

Page 27 (7m 6s)

Replace Atlast content with new content added in the next 3 slides.

Page 29 (7m 26s)

Antimicrobial Testing Leadership and Surveillance (ATLAS): Pfizer’s landmark surveillance database.

Page 30 (7m 56s)

ATLAS: Key Features. Heatmaps: interactive heatmaps illustrating antimicrobial resistance and phenotypic distribution of isolates Database: MIC distribution, susceptibility and resistance data on various pathogens Provide real-time in vitro susceptibility data on a breadth of antibiotics Data can be exported in spreadsheet format or images (including graphs and tables) Data can be searched based on EUCAST or CLSI breakpoints using filters: countries, regions, genus, species, years, phenotype, genotype, ward source (emergency room, ICU, surgery, clinic, etc.), specimen source (body fluids, CNS, GI, lymph, etc.).

Page 31 (8m 35s)

Remove the references from here and add it at the end of the video. References of the content can be mentioned either beneath each slide or all together in the end.

Page 32 (8m 51s)

Pfizer vertical final ideo COMMITMENT TOWARDS MEDICAL EDUCATION A global education resourc to provide support for managing local _challenaesimthetreatmentof_ serious infections in the Indian 0303 1040 AM (x 4/4/2022.

Page 33 (9m 3s)

The #joyofdigital at Pfizer.

Page 34 (9m 9s)

Omnichannel touchpoints. Omnichannel project. Doctor Network Platform promotions.

Page 35 (9m 27s)

Start now http://indiamcs.in. “India MCS” Brought to you by Pfizer – A unique immersive experience for HCPs in form of video case stories & quizzes..

Page 36 (9m 39s)

A one stop solution. Web portals for HCPs. Pfizer for professionals.

Page 37 (9m 52s)

Gamification project on Anti-microbial Stewardship.

Page 38 (10m 11s)

Customised Video detailing. Recorded video messages are shared with healthcare professionals via a customized email.

Page 39 (10m 21s)

Pfizer vertical final ideo COMMITMENT TOWARDS MEDICAL EDUCATION A global education resourc to provide support for managing local _challenaesimthetreatmentof_ serious infections in the Indian 0303 1040 AM (x 4/4/2022.